DailyMarkets.com - Honeywell In-Line With Estimate
DailyMarkets.com - Honeywell In-Line With Estimate |
- Honeywell In-Line With Estimate
- Praxair Wins Contract In Mexico
- Cotton Costs Dampen Hanesbrands’ 1Q
- Expeditors Sees Less Profit In Q1
- HGSI Turns Down Glaxo’s Offer
- Altera Misses By A Penny
- TCF Financial Reports Loss, Rev Up
- Rambus Reports Loss In Q1
- Revenues Slip At Actelion
- Dow Gets Boost From Earnings
Honeywell In-Line With Estimate Posted: 20 Apr 2012 10:00 AM PDT Honeywell International Inc.'s (NYSE:HON) reported first-quarter 2012 earnings results before the market opened today. Earnings per share from continuing operations were $1.04 in the reported quarter, inline with the Zacks Consensus Estimate. The company had a good quarter with its earnings increasing at double digit rate. Margins expanded by 70 bps. |
Praxair Wins Contract In Mexico Posted: 20 Apr 2012 09:50 AM PDT Industrial gas producer and supplier, Praxair Inc. (NYSE:PX) takes a step forward in strengthening its foothold in the industrial belts of Mexico. Recently, the company announced a contract with the Mexican steel major, Deacero. The contract is expected to provide Praxair opportunities to tap the growing needs of gases in Mexico. |
Cotton Costs Dampen Hanesbrands’ 1Q Posted: 20 Apr 2012 09:35 AM PDT Hanesbrands Inc. (NYSE:HBI) reported loss per share of 27 cents in its first quarter 2012, down 155.1% from the prior-year quarter. However, the company fared well as compared with the Zacks Consensus Estimate of a loss of 33 cents per share. |
Expeditors Sees Less Profit In Q1 Posted: 20 Apr 2012 09:25 AM PDT One of the leading third-party logistic (3PL) providers, Expeditors International of Washington Inc. (NASDAQ:EXPD) announced its first quarter 2012 earnings estimates in the range of 35–37 cents per share. |
Posted: 20 Apr 2012 09:10 AM PDT Human Genome Sciences, Inc. (NASDAQ:HGSI) recently rejected GlaxoSmithKline's (NYSE:GSK) offer to acquire the company for $13 per share in cash. Human Genome's board of directors rejected the offer as they believe that the offer price undervalues the company. The offer price of $13 per share represents an 81% premium over Human Genome's closing share price on April 18, 2012. |
Posted: 20 Apr 2012 08:50 AM PDT Chipmaker Altera Corporation (NASDAQ:ALTR) reported sales of $383.8 million in the first quarter of 2012, down 16% sequentially and 28% year over year. |
TCF Financial Reports Loss, Rev Up Posted: 20 Apr 2012 08:35 AM PDT TCF Financial Corporation (NYSE:TCB) reported first-quarter 2012 adjusted net loss of $1.78 per share, better than the Zacks Consensus Estimate loss of $1.81. Adjusted figure includes after-tax charge of $1.87 per share, associated with the repositioning of certain investments and borrowings of TCF Financial's balance sheet. |
Posted: 20 Apr 2012 08:25 AM PDT Rambus Inc. (NASDAQ:RMBS) posted first quarter 2012 adjusted loss per share of 3 cents, missing the Zacks Consensus Estimate of a penny. Adjusted earnings per share exclude other patent royalties received, acquisition costs and retention bonus, amortization, costs of restatement and related legal activities, as well as non-cash interest expense on convertible notes but include stock-based compensation expenses. Shares plunged 3.75% in the after hours. |
Posted: 20 Apr 2012 08:10 AM PDT Actelion Ltd. (ALIOF) reported first quarter 2012 earnings of 71 cents per American Depository Receipt (ADR), down 49% from the prior-year earnings of $1.39. Results were hurt by lower revenues. Earnings were above the Zacks Consensus Estimate of 66 cents. |
Posted: 20 Apr 2012 08:10 AM PDT 04/20/12 US stocks opened higher following strong earnings from key Dow components. An improvement in German business confidence eased some concerns over … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards |
You are subscribed to email updates from DailyMarkets.com To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
Google Inc., 20 West Kinzie, Chicago IL USA 60610 |
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home